Hyphens Pharma International Limited Share Price

Equities

1J5

SG1EE4000006

Pharmaceuticals

Delayed Singapore S.E. 05:58:21 29/04/2024 BST 5-day change 1st Jan Change
0.27 SGD 0.00% Intraday chart for Hyphens Pharma International Limited -1.82% -5.26%

Financials

Sales 2024 * 183M 134M 10.73B Sales 2025 * 192M 141M 11.25B Capitalization 83.36M 61.32M 4.89B
Net income 2024 * 11M 8.09M 646M Net income 2025 * 12M 8.83M 704M EV / Sales 2024 * 0.46 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 0.43 x
P/E ratio 2024 *
7.51 x
P/E ratio 2025 *
6.95 x
Employees 431
Yield 2024 *
3.93%
Yield 2025 *
4.13%
Free-Float 18.12%
More Fundamentals * Assessed data
Dynamic Chart
1 week-1.82%
Current month+1.89%
1 month-1.82%
3 months-5.26%
6 months-1.82%
Current year-5.26%
More quotes
1 week
0.27
Extreme 0.27
0.28
1 month
0.27
Extreme 0.265
0.28
Current year
0.27
Extreme 0.265
0.31
1 year
0.27
Extreme 0.265
0.35
3 years
0.27
Extreme 0.265
0.38
5 years
0.18
Extreme 0.18
0.63
10 years
0.16
Extreme 0.16
0.63
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 31/12/97
Director of Finance/CFO - 31/12/22
Chief Operating Officer 59 31/08/19
Members of the board TitleAgeSince
Director/Board Member 59 22/04/18
Director/Board Member 52 04/11/20
Chief Executive Officer 56 31/12/97
More insiders
Date Price Change Volume
29/04/24 0.27 0.00% 24 500
26/04/24 0.27 -1.82% 57,600
25/04/24 0.275 0.00% 57,000
24/04/24 0.275 0.00% 39,900
23/04/24 0.275 0.00% 40,000

Delayed Quote Singapore S.E., April 29, 2024 at 05:58 am

More quotes
Hyphens Pharma International Limited is a Singapore-based specialty pharmaceutical and consumer healthcare company. The Company's principal activities are those of an investment holding company and provision of management services. The Company's segments include Specialty pharma principals, Proprietary brands, and Medical hypermart and digital. The Specialty pharma principals segment is engaged in the business of marketing and selling a range of specialty pharmaceutical products with exclusivity in the relevant ASEAN countries. The Proprietary brands segment is engaged in the business of developing, marketing and selling its own proprietary range of dermatological products and health supplement products. The Medical hypermart and digital segment is a wholesaler of pharmaceuticals and medical supplies in Singapore, which the Company and its subsidiaries position themselves as a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.27 SGD
Average target price
0.35 SGD
Spread / Average Target
+29.63%
Consensus

Annual profits - Rate of surprise